Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis

Eur J Clin Pharmacol. 2021 Oct;77(10):1583-1585. doi: 10.1007/s00228-021-03128-7. Epub 2021 May 12.

Authors

Massimo Tempestilli¹, Giulia Valeria Stazi¹, Gaetano Maffongelli¹, Maria Cristina Marini¹, Tommaso Ascoli Bartoli¹, Giuseppe Ippolito¹, Emanuele Nicastri¹, Luisa Marchioni¹, Chiara Agrati²

Affiliations

¹ Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, via Portuense 292, 00149, Rome, Italy.
² Immunology and Pharmacology Laboratory, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, via Portuense 292, 00149, Rome, Italy. chiara.agrati@inmi.it.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenosine Monophosphate / analogs & derivatives*
Adenosine Monophosphate / blood
Adenosine Monophosphate / metabolism
Adenosine Monophosphate / therapeutic use
Alanine / analogs & derivatives*
Alanine / blood
Alanine / metabolism
Alanine / therapeutic use
Antiviral Agents / blood*
Antiviral Agents / metabolism*
Antiviral Agents / therapeutic use
COVID-19 Drug Treatment*
Continuous Renal Replacement Therapy
Female
Humans
Middle Aged

Substances

Antiviral Agents
remdesivir
Adenosine Monophosphate
Alanine